promising biotech, page-12

Looking good, as expected. Cephalon will exercise, convert the notes and take the drug to approval. Management will likely be replaced and we will be in the hands of a genuine US Pharma!. First stop 0.70c but expect it will go higher as approval approaches. The US biotech investors that follow Cephalon and are aware of the OMAPRO story and will want to be aboard once Cephalon exercise and validate the data and as a result, the story.Just my opinion of course, I have no "inside information", but this surely is the most likely scenario.